$ALMS

ALUMIS INC. (ALMS): Submission of Matters to a Vote of Security Holders

ALUMIS INC. (ALMS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001847367 0001847367 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Original reporting
Published Jul 2, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 2, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$ALMS
Neutral
high confidence
Mentioned
$ALMS
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ALMSNeutralLow
01

Why it matters

The disclosed outcomes are procedural (board elections; ratification of PwC as independent auditor) and do not introduce new financial metrics, guidance, or enforcement actions.

02

Market read

Primarily informational for governance tracking; not a catalyst for fundamental repricing based on the text provided.

03

What to watch

Traders may still check the referenced May 18, 2026 definitive proxy for any proposals or risk disclosures not captured in this brief 8-K summary.

Relevance 6/10Novelty 2/10Timing: Filed July 2, 2026 after the June 30, 2026 annual meeting vote results.

Background

The filing is SEC Form 8-K Item 5.07, summarizing matters voted on at Alumis’ June 30, 2026 annual meeting; the full details are in the May 18, 2026 definitive proxy.

Company-level read

Ticker impact

$ALMSNeutralHigh confidence
Context

ALUMIS reported 2026 annual meeting voting results, including election of directors and ratification of PricewaterhouseCoopers as auditor.

Expected impact

Limited near-term impact; any move would likely be noise around governance mechanics rather than fundamentals.

Evidence & confidence

The 8-K item is a standard post-meeting disclosure (director elections and auditor ratification) with no new operating, financial, or legal developments.

Market effects

None—this is company-specific governance reporting with no sector-wide signal.

None indicated; no cross-border or macro linkage in the filing.

None—no global deal, regulation, or market-wide catalyst mentioned.

Counterpoint

Director election and auditor ratification can sometimes precede strategic shifts, but this filing provides no such details.

Key entities

  • ALUMIS INC.

    Subject of the 8-K; reported annual meeting voting results for director elections and auditor ratification.

  • PricewaterhouseCoopers LLP

    Ratified by stockholders as independent auditor for the fiscal year ending December 31, 2026.

Related articles

$ALMSMedAI 8/10

Alumis Phase 2b LUMUS Trial Misses Endpoints; Stock Plunges

Alumis Inc. (ALMS) reported Phase 2b LUMUS trial results for Envudeucitinib in SLE, missing primary and secondary endpoints overall but showing promise in a subset of patients with high interferon gene signature. The drug demonstrated improvements in several measures in this subgroup and was well tolerated. The company plans to discuss Phase 3 development with regulators. ALMS stock fell over 55% in pre-market trading.

$ALMSHighAI 8/10

Why is Alumis stock collapsing today?

Alumis stock fell 54.2% in pre-market trading after its Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus missed primary and secondary endpoints. A subgroup of patients showed positive responses, but the overall trial population was under-represented. The company plans to discuss a Phase 3 program with regulators. The Nasdaq, S&P 500, and Dow Jones also declined, exacerbating the sell-off.

$ALMSHighAI 8/10

Alumis stock tumbles 55% after lupus drug trial misses goals

Alumis Inc. (ALMS) shares dropped 55% after its Phase 2b LUMUS trial for envudeucitinib in lupus failed primary and secondary endpoints. The trial enrolled 408 patients but showed improvements only in a subgroup with high interferon gene signature (IFNGS-high). The drug was well-tolerated, and the company plans to discuss Phase 3 development for this subgroup with regulators. Alumis remains on track to submit a New Drug Application for psoriasis in Q4 2026.

$ALMSLowAI 8/10

Alumis Inc.: Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)

Alumis Inc. (ALMS) reported that its Phase 2b LUMUS trial of envudeucitinib for systemic lupus erythematosus (SLE) did not meet primary and secondary endpoints in the overall population. However, a prespecified subgroup of patients with high interferon gene signature (IFNGS-high) showed robust responses. The company plans to discuss Phase 3 development with regulators. Envudeucitinib was well tolerated. Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psor